Document Detail

Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
MedLine Citation:
PMID:  21610513     Owner:  NLM     Status:  Publisher    
OBJECTIVES: Current guidelines recommend the use of multiple medications for hypertension. The present study was aimed at determining which combination was optimal to prevent cardiovascular events. METHODS: We conducted a prospective, randomized, open-label, blinded-endpoint trial. Hypertensive outpatients aged between 40 and 85 years who did not achieve target blood pressure (BP<140/90 mmHg) with calcium channel blocker (CCB) benidipine 4 mg/day were randomly assigned to receive angiotensin receptor blocker (ARB), β-blocker, or thiazide diuretic in addition to benidipine. RESULTS: Among a total of 3501 patients (1167, benidipine-ARB; 1166, benidipine-β-blocker; and 1168, benidipine-thiazide), 3293 patients (1110, 1089, and 1094, respectively) who received each combination treatment were included in the analysis. Median follow-up was 3.61 years. At the end of the treatment, 64.1, 66.9, and 66.0% of patients in the benidipine-ARB, benidipine-β-blocker, and benidipine-thiazide groups achieved target BP, respectively. The cardiovascular composite endpoint occurred in 41 (3.7%), 48 (4.4%), and 32 (2.9%) patients, respectively: the hazard ratio was 1.26 in the benidipine-ARB (P = 0.3505) and 1.54 in the benidipine-β-blocker (P = 0.0567) groups compared with the benidipine-thiazide group. The secondary analyses revealed that benidipine and thiazide diuretic significantly reduced the incidence of fatal or nonfatal strokes (P = 0.0109) and benidipine and ARB significantly reduced new-onset diabetes (P = 0.0240) compared with benidipine and β-blocker. All trial treatments were safe and well tolerated. CONCLUSION: CCB combined with ARB, β-blocker, or thiazide diuretic was similarly effective for the prevention of cardiovascular events and the achievement of target BP.
Masunori Matsuzaki; Toshio Ogihara; Seiji Umemoto; Hiromi Rakugi; Hiroaki Matsuoka; Kazuyuki Shimada; Keishi Abe; Norihiro Suzuki; Tanenao Eto; Jitsuo Higaki; Sadayoshi Ito; Akira Kamiya; Kenjiro Kikuchi; Hiromichi Suzuki; Chuwa Tei; Yasuo Ohashi; Takao Saruta;
Related Documents :
11322273 - Short-term efficacy and safety of stavudine in pretreated hiv-infected patients.
11694773 - Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
20106363 - Cardiopulmonary bypass flow rate: a risk factor for hyperlactatemia after surgical repa...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-22
Journal Detail:
Title:  Journal of hypertension     Volume:  -     ISSN:  1473-5598     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
aYamaguchi University, Ube, Japan bOsaka University, Osaka, Japan cDokkyo Medical University, Tochigi, Japan dJichi Medical University, Tochigi, Japan eSendai Social Insurance Hospital, Sendai, Japan fKeio University, Tokyo, Japan gUniversity of Miyazaki, Miyazaki, Japan hEhime University, Ehime, Japan iTohoku University, Sendai, Japan jAsahikawa Medical College, Asahikawa, Japan kSaitama Medical University, Iruma Saitama, Japan lKagoshima University, Kagoshima, Japan mUniversity of Tokyo, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Next Document:  Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with t...